Description: Figure 19 shows the odds ratios for the meta-analyses on BRCA1 carriers. The odds ratio was 0.55 (95% CI, 0.47 to 0.66) for the four studies of ovarian cancer incidence in patients with the BRCA1 gene as a function of OC use.

Figure 19Forest plot for BRCA1 carriers (ovarian cancer incidence)

CI = confidence interval; OC = oral contraceptive

From: 2, Oral Contraceptives and Ovarian Cancer

Cover of Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer
Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer.
Evidence Reports/Technology Assessments, No. 212.
Havrilesky LJ, Gierisch JM, Moorman PG, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.